Efficiency of Oral N-acetylcyeteine for Chronic Pneumonia

doi:10.3877/cma.j.issn.1674-6902.2017.03.005

Abstract

Abstract:

Objective

To investigate the clinical effect of N-acetylcyeteine in patients with chronic pneumonia, and explore a new approach of treatment to chronic pneumonia.

Methods

A total of 54 patients with chronic pneumonia were recruited into this study from the First Affiliated Hospital of Hainan Medical University between January 2012 and December 2015, and randomly divided into the following four groups: group A(n=11) received N-acetylcyeteine 0.6 g a day, group B(n=13) received N-acetylcyeteine 1.2 g a day, group C(n=15) received N-acetylcyeteine 1.8 g a day and group D(n=15) received without medication(control group). The patients were monitored monthly for 24 weeks. A complete blood count, blood chemistries, SpO₂ and chest CT were recorded before and after therapy. In addition, chest CT was performed at week 4 and week 12.

Results

In comparation with the contrast group or group A, group B or group C could effectively decrease CT scores in patients with chronic pneumonia (P<0.05). But there was no significant difference between group B and group C(P=0.42).

Conclusion

Oral N-acetylcysteine can be used in chronic pneumonia. Recommended dosage of N-acetylcysteine in patients with chronic pneumonia is 1.2 g or 1.8 g a day for 24 week.

Key words: Chronic pneumonia, N-acetylcyeteine, Clinical efficiency, Clinical research

huaping Huang, feng Liu, mingjing Chen, Jie Wang, meihua Liu, Jialiang Chen, xi Li. Efficiency of Oral N-acetylcyeteine for Chronic Pneumonia[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(03): 267-270.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.03.005

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I03/267

Figures/Tables 5

References 15

1	Avijgan M. Specificity and sensitivity of clinical diagnosis for chronic pneumonia[J]. East Mediterr Health J, 2005, 11(5-6): 1029-1037.
2	张智健. N-乙酰半胱氨酸在呼吸系统疾病中的应用[J]. 中国药物应用与监测，2007, 4(2): 20-22.
3	陈业庭，段长华，张伯生，等. 机化性肺炎的诊断和外科治疗[J]. 皖南医学院学报，1998, 17(2): 200-201.
4	徐军，于凤侠. 局灶机化性肺炎12例报告[J]. 济宁医学院学报，2000(02): 81-82.
5	黄华萍，李羲. 应用N-乙酰半胱氨酸治疗慢性肺炎4例并文献复习[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(5): 412-415.
6	中华医学会呼吸病学分会. 社区获得性肺炎诊断和治疗指南[J]. 中华结核和呼吸杂志，2006, 29(10): 651-655.
7	殷人易. 扶正解毒化瘀颗粒对老年肺炎胸片吸收影响的研究[D]. 北京中医药大学，2012.
8	邓莹莹，陆普选，杨桂林，等. 甲型H1N1流感肺炎的胸部CT表现及动态变化特点[J]. 中国医学影像技术，2010, 26(6): 1108-1111.
9	Gera K, Roshan R, Varma-Basil M, et al. Chronic pneumonia due to Klebsiella oxytoca mimicking pulmonary tuberculosis[J]. Pneumonol Alergol Pol, 2015, 83(5): 383-386.
10	Wu DQ, Cheng H, Wang C, et al. Genome sequence of Pseudomonas aeruginosa strain AH16, isolated from a patient with chronic pneumonia in China[J]. J Bacteriol, 2012, 194(21): 5976-5977.
11	徐凌，蔡柏蔷. N-乙酰半胱氨酸在肺部疾病中的应用进展[J]. 国际呼吸杂志，2004, 24(6): 413-416.
12	Fowdar K, Chen H, He Z, et al. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review[J]. Heart Lung, 2017, 46(2): 120-128.
13	Miyake N, Miyamoto S. Effectiveness of N-acetylcysteine in the treatment of schizophrenia[J]. Nihon Shinkei Seishin Yakurigaku Zasshi, 2016, 36(2): 29-35.
14	Salve V T, Atram J S. N-Acetylcysteine combined with home based physical activity: Effect on health related quality of life in stable COPD patients-A randomised controlled trial[J]. J Clin Diagn Res, 2016, 10(12): C16-C19.
15	Santus P, Corsico A, Solidoro P, et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine[J]. COPD, 2014, 11(6): 705-717.

吸收判定	级别评价	总得分评价(%)
完全吸收	Ⅳ-Ⅰ级降至0级	下降≥95
大部分吸收	Ⅳ、Ⅲ级降至Ⅱ、Ⅰ级	下降≥70，<95
部分吸收	Ⅳ级降至Ⅲ级；Ⅱ级降至Ⅰ级	下降≥30，<70
无吸收	无降级	下降≥0，<30
炎症进展	级别上升	得分上升

吸收判定	级别评价	总得分评价(%)
完全吸收	Ⅳ-Ⅰ级降至0级	下降≥95
大部分吸收	Ⅳ、Ⅲ级降至Ⅱ、Ⅰ级	下降≥70，<95
部分吸收	Ⅳ级降至Ⅲ级；Ⅱ级降至Ⅰ级	下降≥30，<70
无吸收	无降级	下降≥0，<30
炎症进展	级别上升	得分上升

项　目	NAC0.6 g/d组(n＝11)	NAC 1.2 g/d组(n＝13)	NAC 1.8 g/d组(n＝15)	对照组(n＝15)	F值	P值
Age(year)	48.55±11.99	42.85±8.90	47.80±13.32	48.47±10.39	0.76	0.52
Male	1.55±0.52	1.54±0.52	1.40±0.51	1.47±0.52	0.24	0.87
Course(d)	120.18±27.29	115.92±25.20	119.20±26.75	116.87±24.38	49.74	0.07
WBC(10⁹/L)	6.55±2.41	6.78±2.13	7.71±2.37	7.13±1.81	3.40	0.72
N(%)	53.09±11.95	52.73±12.13	55.73±11.85	56.13±11.58	46.23	0.33
SpO₂(%)	97.45±0.93	98.00±0.82	97.27±0.96	97.40±0.51	1.41	2.12
胸部CT评分	6.82±1.54	6.69±1.65	6.53±1.69	7.00±1.60	0.58	0.22

项　目	NAC0.6 g/d组(n＝11)	NAC 1.2 g/d组(n＝13)	NAC 1.8 g/d组(n＝15)	对照组(n＝15)	F值	P值
Age(year)	48.55±11.99	42.85±8.90	47.80±13.32	48.47±10.39	0.76	0.52
Male	1.55±0.52	1.54±0.52	1.40±0.51	1.47±0.52	0.24	0.87
Course(d)	120.18±27.29	115.92±25.20	119.20±26.75	116.87±24.38	49.74	0.07
WBC(10⁹/L)	6.55±2.41	6.78±2.13	7.71±2.37	7.13±1.81	3.40	0.72
N(%)	53.09±11.95	52.73±12.13	55.73±11.85	56.13±11.58	46.23	0.33
SpO₂(%)	97.45±0.93	98.00±0.82	97.27±0.96	97.40±0.51	1.41	2.12
胸部CT评分	6.82±1.54	6.69±1.65	6.53±1.69	7.00±1.60	0.58	0.22

组别/时间	治疗前	治疗第4周	治疗第12周	治疗第24周	F值	P值
NAC0.6/d组	6.82±1.54	6.82±1.54	6.18±0.98	5.82±0.98	0.67	0.42
NAC 1.2/d组	6.69±1.65	6.54±1.39	5.85±1.21	1.92±1.12	9.87	0.00
NAC 1.8/d组	6.53±1.69	6.40±1.50	5.33±1.18	1.40±0.91	15.96	0.00
对照组	7.00±1.60	7.00±1.60	6.87±1.41	6.53±1.55	－	－

Please choose a citation manager

Content to export